ABBV (AbbVie) Loans Receivable: $0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABBV AbbVie Inc ABBV
76 GF Score
Price $254.39
GF Value $212.53
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Loans Receivable?

AbbVie ABBV +4.21% 76 Loans Receivable is $0 Mil as of Mar. 2026. GuruFocus rates ABBV with a GF Score™ of 76/100 and a GF Value™ of $212.53 (Modestly Overvalued). The stock has 4 warning signs investors should review.

AbbVie's Loans Receivable for the quarter that ended in Mar. 2026 was $0 Mil.

AbbVie Loans Receivable Historical Data

* Premium members only.

The historical data trend for AbbVie's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Loans Receivable Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ABBV
76GF Score
AbbVie Inc ABBV
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0 Mil mean?
AbbVie (ABBV) has a Loans Receivable of $0 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on AbbVie and its competitors.
Is AbbVie's Loans Receivable too high?
AbbVie's current Loans Receivable is $0 Mil. Overall, AbbVie has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Loans Receivable compare to MRK and JNJ?
AbbVie's Loans Receivable of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on AbbVie and its competitors. AbbVie's current Loans Receivable is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is $212.53, compared to a current price of $254.39 — trading 19.7% above its estimated fair value. The current Loans Receivable is $0 Mil. AbbVie's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For AbbVie (ABBV), the current Loans Receivable is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of $254.39 is trading 19.7% above its estimated GF Value™ of $212.53. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for ABBV:

  • Loans Receivable: $0 Mil
  • GF Value™: $212.53 vs. price of $254.39 (19.7% above fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
76GF Score

Get the complete analysis for ABBV

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$254.39
Price
$212.53
GF Value